Clinical Trials Browser

INDUSTRY × Lymphoma, T-Cell, Cutaneous × mogamulizumab × Clear all

NCT06285370 2025-09-18

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Phase 4 Active not recruiting

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT01226472 2024-04-25

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Phase 2 Completed

1 enrolled 5 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Phase 3 Completed

372 enrolled 14 charts 1 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT04745234 2024-04-25

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Phase 2 Unknown

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous